Iget excited anytime there’s new data published on physician employment. (I’m a researcher after all.) But as the physician market becomes more complex, it’s increasingly difficult to collect meaningful data on physician ownership and employment. One of the biggest reasons for this is that the strict dichotomy between hospital-employed and physician-owned medical groups no longer exists—there’s a lot of gray area that’s hard to capture in a survey.
Author: Praveen Suthrum
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Iterative Scopes, a pioneer in precision medicine technologies for gastroenterology, announced today that it has acquired Clinical Research Strategy Group, LLC and Precision Research (CRSG/Precision), two clinical trial optimization companies focused on streamlining and accelerating the drug development process for inflammatory bowel disease (IBD). The acquisitions deepen Iterative Scopes’ ties to the IBD clinical research community and strengthen its knowledge of the end-to-end research process with a focus on provider viewpoints and pain points.
Illinois Gastroenterology Group recently provided official notice of a data breach that could have broad implications for those whose information was leaked.
Private equity is thriving in gastroenterology, with several equity-backed management groups taking over the market. The number of private equity gastrointestinal groups grew by 28 percent, to 68, in 2021, according to a report jointly published by consulting firm Fraser Healthcare and pharma research firm Spherix Global Insights.
Barrett’s esophagus occurs when cells in the stomach and intestine generate a hybrid, according to new research from the Dana-Farber Cancer Institute, shedding light on this enigmatic condition.
The Lexington, Massachusetts–based firm was founded quietly in 2015 and emerged in 2017 with $65 million in funding. It went public in 2019 and at the end of 2021 had 76 employees. But Kaleido disclosed in January that it had halted work on a drug in Phase 2 studies for chronic obstructive pulmonary disease and ended an agreement with the COPD Foundation.
An article published in Medicine of Metabolic Diseases looks at the developments in research on the gut microbiota and examines new possibilities for management for people with type 2 diabetes.
This month, I’m focusing on how to optimize anti-TNF treatment decisions. The first topic I chose to look at is the use of proactive therapeutic drug monitoring (TDM). Based on limited data, the practice is thought to improve outcomes, but the trial I’ve highlighted—which included patients with IBD and other illnesses treated with infliximab.
Klebsiella pneumoniae, which is found in higher concentrations in patients with inflammatory bowel disease, enhances the growth of Clostridioides difficile and worsens colonic inflammation in the presence of C. difficile infection, according to new research. “When C. difficile infection is superimposed on colitis, it synergistically worsens both conditions,” researcher Taylor Ticer, a PhD candidate at the Medical University of South Carolina, in Charleston, and colleagues reported at the 2022 Crohn’s and Colitis Congress (Inflamm Bowel Dis 2022;28[suppl 1]:S69)
New York, NY (April 19, 2022) — The Canopy Cancer Collective, a national nonprofit organization that strives to fuel better treatments and outcomes for pancreatic cancer patients, has awarded The Tisch Cancer Institute at Mount Sinai a $500,000 grant to support continued innovation in its multidisciplinary treatment of pancreatic cancer.